Azeliragon-d9

Azeliragon-d9 (TTP488-d9) is the deuterium labeled Azeliragon. Azeliragon (TTP488) is an orally bioavailable inhibitor of the receptor for advanced glycation end products (RAGE) in development as a potential treatment to slow disease progression with mild Alzheimer’s disease (AD). Azeliragon also can cross the blood-brain barrier (BBB).

TTP488-d9; PF-04494700-d9

12352005

Amyloid-β; Isotope-Labeled Compounds

Neuronal Signaling; Others

Endocrinology; Neurological Disease

[2H]C([2H])(C([2H])(C([2H])(C([2H])(C1=NC(C2=CC=C(C=C2)OCCCN(CC)CC)=CN1C3=CC=C(C=C3)OC4=CC=C(C=C4)Cl)[2H])[2H])[2H])[2H]

C32H29D9ClN3O2

541.17

[1]Burstein AH, et al. Assessment of Azeliragon QTc Liability Through Integrated, Model-Based Concentration QTc Analysis. Clin Pharmacol Drug Dev. 2019 May;8 (4) :426-435. |[2]Bongarzone S, et al. Targeting the Receptor for Advanced Glycation Endproducts (RAGE) : A Medicinal Chemistry Perspective. J Med Chem. 2017 Sep 14;60 (17) :7213-7232.

Room temperature

http://file.medchemexpress.com/batch_PDF/HY-50682S/

Isotope-Labeled Compounds

No Development Reported